Kefuclav 70 ml

Indications of Kefuclav 70 ml Suspension

Kefuclav 70 ml Suspension is prescribed to treat infections caused by sensitive bacteria.

• Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.
• Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes.
• Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains)
• Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli.
• Acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of Acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains).
• Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes.
• Uncomplicated urinary tract infections caused by E.coli or Klebsiella pneumoniae.
• Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).
• Uncomplicated Gonorrhoea caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae.
• Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi.
• Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E.coli, Haemophilus influenzae (including ampicillin-resistant strains) & Klebsiella spp.
• Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis & Staphylococcus aureus (penicillinase and non-penicillinase producing strains)
• Switch therapy (Injectable to oral)

Pharmacology of Kefuclav 70 ml Suspension

Cefuroxime is a bactericidal second-generation cephalosporin antibiotic that kills a wide spectrum of Gram-positive and Gram-negative bacteria, including many beta-lactamase-producing strains. Cefuroxime works by interfering with the transpeptidation process, which stops bacteria from making cell walls.

Streptomyces clavuligerus produces clavulanic acid, a naturally derived beta lactamase inhibitor. It has a structure comparable to beta lactam antibiotics, and it binds to beta-lactamase enzymes and inactivates them irreversibly. Clavulanic acid protects Cefuroxime against breakdown by beta lactamase enzymes, making it an effective therapy for beta lactamase-related bacterial infections.

Kefuclav 70 ml Suspension Dosage

Adolescents and adults (13 years and older)-

• Pharyngitis/tonsillitis: 250 mg b.i.d. for 5-10 days
• Acute bacterial maxillary sinusitis: 250 mg b.i.d. for 10 days
• Acute bacterial exacerbation of chronic bronchitis: 250-500 mg b.i.d. for 10 days
• Secondary bacterial infections of acute bronchitis: 250-500 mg b.i.d. for 5-10 days 
• Uncomplicated skin and skin structure infections: 250-500 mg b.i.d. for 10 days
• Uncomplicated urinary tract infections: 250 mg b.i.d. for 7-10 days
• Uncomplicated Gonorrhoea: 1000 mg b.i.d. Single dose
• Community acquired pneumonia: 250-500 mg b.i.d. for 5-10 days
• MDR Typhoid Fever: 500 mg b.i.d. for 10-14 days
• Early Lyme disease: 500 mg b.i.d. for 20 days

Paediatric Patients (3 months to 12 years)-

• Pharyngitis/Tonsillitis: 20 mg/kg/day b.i.d for 5-10 days
• Acute otitis media: 30 mg/kg/day b.i.d for 10 days
• Acute bacterial maxillary sinusitis: 30 mg/kg/day b.i.d for 10 days
• Impetigo: 30 mg/kg/day b.i.d for 10 days

Administration of Kefuclav 70 ml Suspension

Cefuroxime-Clavulanic Acid tablets should not be taken with meals.

Interaction of Kefuclav 70 ml Suspension

The area under the serum concentration versus time curve increases by 50% when probenecid and Cefuroxime-Clavulanic Acid are given together. A drug that lowers stomach acidity may diminish Cefuroxime bioavailability and negate the impact of postprandial absorption.

Contraindications of Kefuclav 70 ml Suspension

Kefuclav 70 ml Suspension is not recommended for people who have a documented cephalosporin allergy or who have Pseudomembranous Colitis.

Kefuclav 70 ml Suspension Side Effect

Kefuclav 70 ml Suspension is generally well tolerated. However, nausea, vomiting, diarrhea, stomach discomfort, or pain are possible adverse effects. Prolonged use of Cefuroxime and Clavulanic acid together, like other broad-spectrum antibiotics, can lead to nonsusceptible microorganism overgrowth. Renal failure, allergy, angioedema, and pruritis occur seldom (0.2 percent).

Pregnancy & Lactation

Antibiotics should be avoided if at all feasible throughout the first trimester. Cefuroxime-Clavulanic Acid, on the other hand, can be safely used to treat urinary and other infections later in pregnancy. Cefuroxime-Clavulanic Acid is excreted in tiny amounts in breast milk. However, the potential of the child being sensitized should be considered.

Precautions & Warnings

Cefuroxime should be used with caution in individuals who are taking strong diuretics and have a history of colitis.

Therapeutic Class

Second generation Cephalosporins

Storage Conditions

Store in a cool, dry place (below 30o C), away from light and moisture. Keep out of the reach of children.

Pharmaceutical Name of Kefuclav 70 ml Suspension

Eskayef Pharmaceuticals Ltd.

Generic

Cefuroxime Axetil + Clavulanic Acid